Premium
Determining the optimal dose and schedule of sunitinib
Author(s) -
Suarez Cristina,
Rini Brian I.
Publication year - 2011
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.26426
Subject(s) - medicine , sunitinib , schedule , intensive care medicine , cancer , computer science , operating system
Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptors. In this issue, Barrios et al present a study in which 120 treatment‐naive patients with metastatic RCC were enrolled in a single‐arm, open‐label, phase 2 trial of continuous once‐daily sunitinib. This study and other data provide insight into optimal dosing of sunitinib in metastatic RCC.